AnPac Bio-Medical: Rises on 11% jump in cancer detection tests from June qtr

Fresh2

26/10/2020 12:15

** U.S.-listed shares of Chinese biotech co  ANPC.O  rise
5.6% to $3.79 premarket
    ** ANPC posts ~11% jump in its cancer detection tests to
over 200,000 by Sept. 30, from the qtr ended June
    ** The tests use cancer differentiation analysis (CDA),
which measures bio-physical signals in the blood
 urn:newsml:reuters.com:*:nFWN2HH0S0 urn:newsml:reuters.com:*:nGNX9zGpsm
    ** The CDA technology allows cancer screening for close to
60 types of cancer, including esophageal cancer and brain tumors
    ** ANPC has two certified clinical labs in China and one in
the U.S., where it performs a suite of cancer screening and
detection tests
    ** In Sept. co reported positive data from a cancer
monitoring tech study  urn:newsml:reuters.com:*:nL4N2G12I4
    ** Only one brokerage covers the stock, with a "buy" rating
and PT of $12.50 - Refinitiv data
    ** Stock down 68% YTD since Jan. 30 IPO

 (Reporting by Devik Jain in Bengaluru)
 ((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2062; ;))